The American Journal of Managed Care7h
Nipocalimab’s Promising Potential in Advancing gMG Care
For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
Urine test offers simpler diagnosis for mitochondrial disorders, study finds
New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...
Guillain-Barre Syndrome: Know About The Symptoms And The Urgent Need For Early Diagnosis
Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...
'I woke up with a droopy eyelid - then rare diagnosis changed my family's life'
Abby Smith, 40, a NHS manager from Reading, has the rare autoimmune disease myasthenia gravis, which means she needs her ...
The American Journal of Managed Care4d
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Neurological conditions that mimic Guillain-Barré Syndrome and how to differentiate them
GBS, a neurological condition triggered by an overactive immune system often after viral or bacterial infections, has been ...
STAT5d
Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.